RBL2 Regulates Cardiac Sensitivity to Anthracycline Chemotherapy.

Peng Xia,Jingrui Chen,Yadav Sapkota,Erika N Scott,Yuening Liu,Melissa M Hudson,Shahrad R Rassekh,Bruce C Carleton,Colin J D Ross,Eric J Chow,Zhaokang Cheng

JACC: CardioOncology（2023）

引用 0|浏览3

暂无评分

摘要

Rbl2 is an endogenous CDK2 inhibitor in the heart and represses FOXO1-mediated proapoptotic gene expression. The loss of Rbl2 increases sensitivity to DOX-induced cardiotoxicity. Our findings suggest that could be used as a biomarker to predict the risk of cardiotoxicity before the initiation of anthracycline-based chemotherapy.

查看译文

关键词

cancer therapy,cardiomyopathy,cardiotoxicity,cell cycle,cell death,doxorubicin,genetics,heart failure,mechanisms,tumor

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要